

Editorial

Non-Invasive Breath Analysis for Disease Screening and Diagnoses

Hyun Jin Jung and Ronny Priefer * 

Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA 02115, USA; hjung1@stu.mcphs.edu

* Correspondence: ronny.priefer@mcphs.edu

Lower respiratory infections are a deadly communicable disease ranked as the fourth leading cause of death globally, with nearly 2.6 million succumbing annually [1]. Acute lower respiratory tract infections in children have sadly been shown to increase the risk of developing a chronic respiratory disease later in life. Additionally, respiratory tract infections caused by influenza kill between 250,000 and 500,000 people globally and costs between USD 71 and 167 billion annually [2]. Early detection and accurate diagnosis of infectious disease are important to ultimately improve the effectiveness of treatments, determine the correct use of antibiotics, avoid long-term complications, and help prevent or stop an outbreak.

Many different laboratory tests are currently used to identify infectious microorganisms. These include tests on blood, urine, tissue, cerebrospinal fluid, stool, sputum, and mucus from the nose or throat, as well as fluid from the genital area [3]. These existing methods can also be divided into either invasive or non-invasive. Invasive methods include esophagogastroduodenoscopy (EGD), with collection for gastric biopsies and subsequent histological staining. It is often used to detect *Helicobacter pylori* infection in the gut. This is expensive, causes patient discomfort, and sometimes yields false negative results due to sampling errors. However, there are a growing number of non-invasive methods for detecting *H. pylori* infection, such as serological, fecal antigen, and ¹³C-urea breath testing (¹³C-UBT) [4,5].

Utilizing the breath to screen or diagnose diseases has become increasingly popular. Human-exhaled breath contains over 3000 volatile organic compounds (VOCs). Breath VOCs are produced by our own biologic processes, as well as by microorganisms as part of their metabolism. These can be detected and quantified utilizing various instrumentations, such as gas chromatography/mass spectrometry or eNose detection [6]. These and other advanced technologies specifically examine the volatile metabolic fingerprints generated by our body and its microorganism flora in order to discriminate between different aliments. Thus, VOCs are being evaluated extensively as potential biomarkers and as a non-invasive approach to analyze a multitude of diseases, such as diabetes, lactose intolerance, cancer, infections, [7–9] and/or lifestyle choices, such as keto-diet [10] or cannabis use [11]. For example, Gastric Emptying Breath Test (GEBT), H₂ breath monitoring, and NIOX[®] are FDA-approved tests [7,12,13]. GEBT is used to diagnose gastroparesis, H₂ breath analysis is used for the diagnosis of lactose intolerance [9], and NIOX measures markers for airway inflammation. By identifying disease-specific biomarkers, early detection could prevent serious complications, lowering mortality rates and reducing the unnecessary use of medicines.

With the fantastic advances in technology, especially nanotechnology, the opportunity to use these in the realm of healthcare, specifically to detect small quantities of biomarkers, is an obvious next step. This Special Issue, “Non-invasive Medical Devices for Detection and Monitoring within Healthcare”, is designed not only to showcase what has already been



Citation: Jung, H.J.; Priefer, R. Non-Invasive Breath Analysis for Disease Screening and Diagnoses. *Biosensors* **2022**, *12*, 235. <https://doi.org/10.3390/bios12040235>

Received: 31 March 2022

Accepted: 5 April 2022

Published: 12 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

accomplished to improve detection efficacy, but also the translation of these advancements into improving patient experiences and outcomes.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Acknowledgments: The authors wish to thank the School of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences University for their financial support of this project.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Health Organization. *The Top 10 Causes of Death Fact Sheet*; World Health Organization: Geneva, Switzerland, 2020.
2. Forum of International Respiratory Societies. *The Global Impact of Respiratory Disease*, 2nd ed.; European Respiratory Society: Sheffield, UK, 2017.
3. Ratiu, I.A.; Ligor, T.; Bocos-Bintintan, V.; Szeliga, J.; Machała, K.; Jackowski, M.; Buszewski, B. GC-MS application in determination of volatile profiles emitted by infected and uninfected human tissue. *J. Breath Res.* **2019**, *13*, 026003. [[CrossRef](#)] [[PubMed](#)]
4. BreathTek UBT [Package Insert]. U.S. Food and Drug Administration Website. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20586s4lbl.pdf (accessed on 9 May 2021).
5. Maity, A.; Som, S.; Ghosh, C.; Banik, G.D.; Daschakraborty, S.B.; Ghosh, S.; Chaudhuri, S.; Pradhan, M. Oxygen-18 stable isotope of exhaled breath CO₂ as a non-invasive marker of helicobacter pylori infection. *J. Anal. At. Spectrom.* **2014**, *29*, 2251–2255. [[CrossRef](#)]
6. Licht, J.-C.; Grasmann, H. Potential of the electronic nose for the detection of respiratory diseases with and without infection. *Int. J. Mol. Sci.* **2020**, *21*, 9416. [[CrossRef](#)] [[PubMed](#)]
7. Argnani, F.; Di Camillo, M.; Marinaro, V.; Foglietta, T.; Avallone, V.; Cannella, C.; Vernia, P. Hydrogen breath test for the diagnosis of lactose intolerance, is the routine sugar load the best one? *World J. Gastroenterol.* **2008**, *14*, 6204–6207. [[CrossRef](#)] [[PubMed](#)]
8. Mazzatenta, A.; Pokorski, M.; Di Giulio, C. Real-time breath analysis in type 2 diabetes patients during cognitive effort. *Adv. Exp. Med. Biol.* **2013**, *788*, 247–253. [[PubMed](#)]
9. Robles, L.; Priefer, R. Lactose Intolerance: What Your Breath Can Tell You. *Diagnostics.* **2020**, *10*, 412. [[CrossRef](#)] [[PubMed](#)]
10. Alkedeh, O.; Priefer, R. The Ketogenic Diet: Breath Acetone Sensing Technology. *Biosensors* **2021**, *11*, 26. [[CrossRef](#)] [[PubMed](#)]
11. Ramzy, V.; Priefer, R. THC detection in the breath. *Talanta* **2021**, *222*, 121528. [[CrossRef](#)] [[PubMed](#)]
12. Bharucha, A.E.; Camilleri, M.; Veil, E.; Burton, D.; Zinsmeister, A.R. Comprehensive assessment of gastric emptying with a stable isotope breath test. *Neurogastroenterol. Motil.* **2013**, *25*, e60–e69. [[CrossRef](#)] [[PubMed](#)]
13. Silkoff, P.E.; Carlson, M.; Bourke, T.; Katial, R.; Ogren, E.; Szefer, S.J. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. *J. Allergy Clin. Immunol.* **2004**, *114*, 1241–1256. [[CrossRef](#)] [[PubMed](#)]